Billings Clinic
Especially For:

Clinical Trials

Title   Lung Cancer: Stage IV, 2nd line
Description   I4T-MC-JVBA(b) A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum- Based Therapy
IRB Number   I4T-MC-JVBA(b)
Category   Lung Cancer
Inclusion/Notes   second line, must have had one platinum based therapy. Squamous histology ok. Prior radiation is ok. Brain mets ok, if treated and stable. No ANSAIDS, no GI issues. No previous Docetaxel
Status   Active
Start Date   02/01/2011
Principal Investigator (PI)   Jorge Nieva, MD
Contact Name   Judy Miller, RN
Contact Email   jmiller4@billingsclinic.org
Phone   (406) 435-7482
Fax   (000) 000-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.